Figure 7. (A–E) After treatment with various siRNAs, including siRNAs against INHBA, CD24, GRAMD1C, NFKBIA, and ACSS2, the viability of MDA-MB-231 and MCF7 breast cancer cells was evaluated by CCK-8 assay.

The data are represented as the mean ± SD (n = 5). * p < 0.05 vs. the control group.